NF-kappa B transcription factors are major drivers of tumor initiation and progression. NF-kappa B signaling is constitutively activated by genetic alterations or environmental signals in many human cancers, where it contributes to almost all hallmarks of malignancy, including sustained proliferation, cell death resistance, tumor-promoting inflammation, metabolic reprogramming, tissue invasion, angiogenesis, and metastasis. As such, the NF-kappa B pathway is an attractive therapeutic target in a broad range of human cancers, as well as in numerous non-malignant diseases. Currently, however, there is no clinically useful NF-kappa B inhibitor to treat oncological patients, owing to the preclusive, on-target toxicities of systemic NF-kappa B blockade. In this review, we discuss the principal and most promising strategies being developed to circumvent the inherent limitations of conventional I kappa B kinase (IKK)/NF-kappa B-targeting drugs, focusing on new molecules that target upstream regulators or downstream effectors of oncogenic NF-kappa B signaling, as well as agents targeting individual NF-kappa B subunits.

The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target

Verzella, Daniela
;
Cornice, Jessica;Vecchiotti, Davide;Di Vito Nolfi, Mauro;Capece, Daria;Zazzeroni, Francesca;
2022-01-01

Abstract

NF-kappa B transcription factors are major drivers of tumor initiation and progression. NF-kappa B signaling is constitutively activated by genetic alterations or environmental signals in many human cancers, where it contributes to almost all hallmarks of malignancy, including sustained proliferation, cell death resistance, tumor-promoting inflammation, metabolic reprogramming, tissue invasion, angiogenesis, and metastasis. As such, the NF-kappa B pathway is an attractive therapeutic target in a broad range of human cancers, as well as in numerous non-malignant diseases. Currently, however, there is no clinically useful NF-kappa B inhibitor to treat oncological patients, owing to the preclusive, on-target toxicities of systemic NF-kappa B blockade. In this review, we discuss the principal and most promising strategies being developed to circumvent the inherent limitations of conventional I kappa B kinase (IKK)/NF-kappa B-targeting drugs, focusing on new molecules that target upstream regulators or downstream effectors of oncogenic NF-kappa B signaling, as well as agents targeting individual NF-kappa B subunits.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/195418
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact